½ÃÀ庸°í¼­
»óǰÄÚµå
1594434

¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀå : ±â±â À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Needle Free Diabetes Care Market by Device Type (Insulin Infuser, Insulin Patches, Insulin Pens), End User (Consumer, Diagnostic Center, Hospitals & Clinic) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 182 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀåÀº 2023³â 138¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ°í 2024³â¿¡´Â 161¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CAGR 16.26%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 398¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ħÀ» »ç¿ëÇÏÁö ¾Ê´Â ´ç´¢º´ Ä¡·á ½ÃÀåÀÇ ¹üÀ§¿¡´Â ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ½Ã½ºÅÛ, Àν¶¸° ÆßÇÁ, Á¦Æ® ÁÖ»ç±â µî ±âÁ¸ÀÇ ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â ´ç´¢º´ Ä¡·á¸¦ À§ÇÑ ±â±â ¹× ±â¼úÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ±â¼úÀÇ Çʿ伺Àº ±âÁ¸ÀÇ ¹Ù´Ã »ç¿ë ¹æ½Ä¿¡ µû¸¥ ºÒÆíÇÔ°ú ºÒÆíÇÔ¿¡¼­ ºñ·ÔµÈ °ÍÀ¸·Î, ȯÀÚÀÇ ¼øÀÀµµ¿Í »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ÁÖ·Î º´¿ø, Áø·á¼Ò, ÀçÅà °£È£ µî ÃÖÁ¾»ç¿ëÀÚ°¡ Ç÷´ç ¸ð´ÏÅ͸µ ¹× Àν¶¸° Åõ¿©¿¡ Àû¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ´ç´¢º´ À¯º´·ü Áõ°¡, ºñħ½ÀÀû ¸ð´ÏÅ͸µ ±â±â¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÇコÄÉ¾î ±â¼úÀÇ ¹ßÀü, ȯÀÚ ÀνÄÀÇ Çâ»óÀ¸·Î ÀÎÇØ Å« ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. R&D ÅõÀÚ ±ÞÁõ°ú ÁÖ¿ä ±â¾÷ °£ÀÇ Àü·«Àû Á¦ÈÞ´Â ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí Â÷º°È­µÈ Á¦Ç°À» Á¦°øÇϱâ À§ÇÑ ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ´ç´¢º´ Àα¸°¡ Áõ°¡Çϰí ÀÇ·á ÀÎÇÁ¶ó°¡ ¹ßÀüÇϰí ÀÖ´Â ½ÅÈï ½ÃÀåµµ ¹Ì°³Ã´ ½ÃÀåÀÔ´Ï´Ù. ±×·¯³ª ¹«¹Ù´Ã ±â±âÀÇ ³ôÀº ºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, ½ÅÈï±¹ Áö¿ªÀÇ ÀÎ½Ä ºÎÁ· µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¼úÀû ÇѰè¿Í ½Å·ÚÇÒ ¼ö ÀÖ´Â µ¥ÀÌÅÍÀÇ Á¤È®¼ºÀÌ Ã¤Å÷üÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦¸¦ ±Øº¹ÇÏ°í ¼ºÀåÀ» ÃËÁøÇϱâ À§ÇØ ±â¾÷µéÀº ³ª³ë±â¼ú ±â¹Ý Àü´Þ ½Ã½ºÅÛ, Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀ» À§ÇÑ ½º¸¶Æ® ¿þ¾î·¯ºí ±â±â, °³ÀÎÈ­µÈ ÇコÄÉ¾î ¼Ö·ç¼ÇÀ» À§ÇÑ IoT¿Í ´ç´¢º´ Ä¡·á ±â±âÀÇ ÅëÇÕ°ú °°Àº Çõ½ÅÀûÀÎ ºÐ¾ß¿¡ ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¿ªµ¿ÀûÀÌ°í °æÀïÀÌ Ä¡¿­Çϸç, ±â¼ú ¹ßÀüÀº Ç×»ó ±× »óȲÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ±â¾÷Àº »ç¿ëÀÚ Ä£È­ÀûÀÎ µðÀÚÀο¡ ÅõÀÚÇϰí, Àú·ÅÇÑ °¡°ÝÀ» º¸ÀåÇϰí, Á¦Ç°ÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» ³ôÀÓÀ¸·Î½á °æÀï·ÂÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ Áß½ÉÀÇ Á¢±Ù ¹æ½Ä°ú ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿ÍÀÇ Çù·Â °ü°è¸¦ °­Á¶ÇÔÀ¸·Î½á ¹Ù´Ã ¾ø´Â ´ç´¢º´ Ä¡·á ºÐ¾ß¿¡¼­ ±¤¹üÀ§ÇÑ Ã¤Åðú ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ[2023] 138¾ï 7,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2024] 161¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2030] 398¾ï 3,000¸¸ ´Þ·¯
CAGR(%) 16.26%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀåÀº ¼ö¿ä¿Í °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ÃËÁø¿äÀÎ
    • ´ç´¢º´ ¹× ºñ¸¸ Àα¸ÀÇ Áõ°¡
    • Áúº´ °ü¸®¿ë ½º¸¶Æ®Æù ¾Û Áõ°¡
    • ´ç´¢º´°ú Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • ½Ã¼³°ú °ü·ÃµÈ ³ôÀº ºñ¿ë ¹× ±â¼úÀû ¿À·ù¿¡ ´ëÇÑ ¿ì·Á
  • ½ÃÀå ±âȸ
    • ´ç´¢º´ Ä¡·á¸¦ À§ÇÑ ±â¼ú ¹ßÀü
    • ħÀ» »ç¿ëÇÏÁö ¾Ê´Â ´ç´¢º´ Ä¡·áÀÇ Ã¤Åà Ȯ´ë
  • ½ÃÀå °úÁ¦
    • ħ¿¡ Âñ¸®°Å³ª ¹Ù´Ã¿¡ Âñ¸° ºÎ»óÀ¸·Î ÀÎÇÑ ³ôÀº °¨¿° À§Ç輺

Porter's Five Forces : ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀåÀ» Ž»öÇϱâ À§ÇÑ Àü·«Àû µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï »óȲÀ» ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀå¿¡¼­ ¿ÜºÎÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¹«¹Ù´Ã ´ç´¢Ä¡·áÁ¦ ½ÃÀåÀÇ °æÀï »óȲ ÆÄ¾Ç

¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀå¿¡¼­ÀÇ °ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï »óȲÀ» öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº ¾îµðÀΰ¡?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õÀÇ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀå : ±â±â À¯Çüº°

  • Àν¶¸° ÁÖÀÔ±â
  • Àν¶¸° ÆÐÄ¡
  • Àν¶¸° Ææ
  • Àν¶¸° ÆßÇÁ
  • Á¦Æ® ÀÎÁ§ÅÍ

Á¦7Àå ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼ÒºñÀÚ
  • Áø´Ü ¼¾ÅÍ
  • º´¿ø¡¤Å¬¸®´Ð

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦11Àå °æÀï »óȲ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Akra Dermojet
  • Antares Pharma, Inc.
  • Bioject Medical Technologies Inc.
  • Echo Therapeutics Inc.
  • European Pharma Group BV
  • Injex Pharma AG
  • MannKind Corporation
  • Medical International Technology, Inc.
  • Pharmajet, Inc.
  • The 3M Company
ksm 24.11.28

The Needle Free Diabetes Care Market was valued at USD 13.87 billion in 2023, expected to reach USD 16.11 billion in 2024, and is projected to grow at a CAGR of 16.26%, to USD 39.83 billion by 2030.

The scope of the needle-free diabetes care market involves devices and technologies aimed at diabetes management without the use of traditional needles, including continuous glucose monitoring (CGM) systems, insulin pumps, and jet injectors. The necessity of these technologies arises from the discomfort and inconvenience associated with traditional needle-based methods, aiming to enhance patient compliance and quality of life. They are applied in monitoring blood glucose levels and administering insulin, primarily by end-users such as hospitals, clinics, and home care settings. The market is significantly influenced by the increasing prevalence of diabetes, growing demand for non-invasive monitoring devices, advancements in healthcare technologies, and rising patient awareness. A surge in R&D investments and strategic collaborations between key players are potential opportunities, as they promote innovation and offer differentiated products. Emerging markets with a growing diabetic population and evolving healthcare infrastructures also present untapped opportunities. However, the market faces challenges such as the high costs of needle-free devices, stringent regulatory requirements, and a lack of awareness in developing regions. Furthermore, technological limitations and reliable data accuracy can impede adoption rates. To foster growth and overcome these challenges, businesses can focus on innovative areas such as nanotechnology-based delivery systems, smart wearable devices for continuous monitoring, and integrating IoT with diabetes care devices for personalized healthcare solutions. The market is dynamic and competitive, with technological advancements consistently shaping its landscape. Companies can gain a competitive edge by investing in user-friendly designs, ensuring affordability, and enhancing the precision and efficiency of their offerings. The emphasis on patient-centric approaches and collaborations with healthcare providers can also promote widespread adoption and market expansion in the needle-free diabetes care domain.

KEY MARKET STATISTICS
Base Year [2023] USD 13.87 billion
Estimated Year [2024] USD 16.11 billion
Forecast Year [2030] USD 39.83 billion
CAGR (%) 16.26%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Needle Free Diabetes Care Market

The Needle Free Diabetes Care Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of diabetes and obese population
    • Increasing number of smartphone apps for disease management
    • Rising awareness regarding the disease and the treatments
  • Market Restraints
    • High cost associated with the facility and concerns regarding technical errors
  • Market Opportunities
    • Technological advancements for diabetes care
    • Growing adoption of needle-free diabetes management
  • Market Challenges
    • High risk of infection because of poking and needle-stick injuries

Porter's Five Forces: A Strategic Tool for Navigating the Needle Free Diabetes Care Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Needle Free Diabetes Care Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Needle Free Diabetes Care Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Needle Free Diabetes Care Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Needle Free Diabetes Care Market

A detailed market share analysis in the Needle Free Diabetes Care Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Needle Free Diabetes Care Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Needle Free Diabetes Care Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Needle Free Diabetes Care Market

A strategic analysis of the Needle Free Diabetes Care Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Needle Free Diabetes Care Market, highlighting leading vendors and their innovative profiles. These include Akra Dermojet, Antares Pharma, Inc., Bioject Medical Technologies Inc., Echo Therapeutics Inc., European Pharma Group BV, Injex Pharma AG, MannKind Corporation, Medical International Technology, Inc., Pharmajet, Inc., and The 3M Company.

Market Segmentation & Coverage

This research report categorizes the Needle Free Diabetes Care Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Device Type, market is studied across Insulin Infuser, Insulin Patches, Insulin Pens, Insulin Pumps, and Jet Injectors.
  • Based on End User, market is studied across Consumer, Diagnostic Center, and Hospitals & Clinic.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diabetes and obese population
      • 5.1.1.2. Increasing number of smartphone apps for disease management
      • 5.1.1.3. Rising awareness regarding the disease and the treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the facility and concerns regarding technical errors
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements for diabetes care
      • 5.1.3.2. Growing adoption of needle-free diabetes management
    • 5.1.4. Challenges
      • 5.1.4.1. High risk of infection because of poking and needle-stick injuries
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Needle Free Diabetes Care Market, by Device Type

  • 6.1. Introduction
  • 6.2. Insulin Infuser
  • 6.3. Insulin Patches
  • 6.4. Insulin Pens
  • 6.5. Insulin Pumps
  • 6.6. Jet Injectors

7. Needle Free Diabetes Care Market, by End User

  • 7.1. Introduction
  • 7.2. Consumer
  • 7.3. Diagnostic Center
  • 7.4. Hospitals & Clinic

8. Americas Needle Free Diabetes Care Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Needle Free Diabetes Care Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Needle Free Diabetes Care Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akra Dermojet
  • 2. Antares Pharma, Inc.
  • 3. Bioject Medical Technologies Inc.
  • 4. Echo Therapeutics Inc.
  • 5. European Pharma Group BV
  • 6. Injex Pharma AG
  • 7. MannKind Corporation
  • 8. Medical International Technology, Inc.
  • 9. Pharmajet, Inc.
  • 10. The 3M Company
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦